Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:RVMD

Revolution Medicines Q3 2026 Earnings Date & Estimates

Revolution Medicines logo
$188.12 -12.75 (-6.35%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$187.80 -0.32 (-0.17%)
As of 04:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Revolution Medicines in Q3 2026

Revolution Medicines is expected to post earnings of -$2.35 per share on revenue of $22.95 million. In the same quarter a year earlier Revolution Medicines reported -$1.61 per share. Revolution Medicines last reported on August 5, 2026, posting -$3.06 per share and missing the -$2.04 consensus estimate. Revolution Medicines has beaten the consensus EPS estimate in 0 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$2.35
Expected Revenue
$22.95 million
Prior-Year EPS
-$1.61

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$3.06 (Missed by -$1.02)
EPS Beat Rate
0 of last 8 quarters

Prepare for the Q3 2026 Call

Revolution Medicines Q3 2026 Earnings FAQ

Revolution Medicines (NASDAQ:RVMD) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

Revolution Medicines' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Revolution Medicines to post earnings of -$2.35 per share for Q3 2026.

The consensus revenue estimate for Revolution Medicines is $22.95 million for Q3 2026.

Revolution Medicines Earnings Headlines

RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rbc-raises-price-target-revolution-114404691.html
Revolution Medicines Begins Phase 3 Trial of Rasonque Combination in Pancreatic Cancer
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-begins-phase-3-134822943.html
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
 |  Weiss Ratings (Ad)
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374500/0/en/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-309-trial-evaluating-rasonque-daraxonrasib-plus-zoldonrasib-as-first-line-treatment-for-metastatic-ras-g12d-pancre.html
Revolution Medicines (NASDAQ: RVMD) CDO sells 6,309 shares under preset plan
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085856
Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold
October 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951778-revolution-medicines-priced-for-a-label-the-trial-didnt-test-hold
See More Revolution Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revolution Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revolution Medicines and other key companies, straight to your email.

About Revolution Medicines

Revolution Medicines (NASDAQ:RVMD) is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers. The company is evaluating these and other candidates in clinical studies across several solid-tumor indications.

Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines conducts its drug-discovery and clinical-development activities primarily in the United States. The company is led by Mark A. Goldsmith, who serves as chairman and chief executive officer.

View Revolution Medicines Profile
Earnings Tools